Cohen & Steers: A Beneficiary Of Challenges In Private Markets

Seeking Profits5.39K FollowersFollow5ShareSavePlay(8min)CommentsSummaryCohen & Steers, Inc. remains a Buy, with public real estate focus and strong fund performance positioning it for renewed inflows as macro headwinds abate.CNS reported Q1 EPS of $0.79 on $144M revenue, with AUM at $93.1B and net inflows more than doubling year-over-year.Shares offer a 4.1% dividend yield, backed by a robust balance sheet and $200M in cash and treasuries, ensuring payout security.I target 8% long-term growth, see CNS stock valuation at 18-20x earnings as justified, and expect shares to migrate into the low-$70s this year.

Getty Images Shares of Cohen & Steers, Inc. (CNS) have been a poor performer over the past year, losing about 11% of their value. The company has, in my view, been weighed down more by macro challenges than problems of its own making. CNSThis article was written bySeeking Profits5.39K FollowersFollowOver fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let me know!Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.